Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib plus endocrine therapy as adjuvant treatment in high-risk HR-positive, HER2-negative early breast cancer
2014-001795-53Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Ribociclib plus endocrine therapy with Placebo plus endocrine therapy (2 arms). Primary endpoint: Invasive disease-free survival. Started Aug 2017; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-001795-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001795-53.